Erdafitinib was approved by the FDA in July 2020 for the treatment of bladder cancer. Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines how the approval of erdafitibib has impacted her practice and the prospects for the future use of the agent, highlighting data from the NORSE and THOR (NCT04009681) trials. This interview was recorded at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.